(Q35542636)

8 August 2017

1 reference

title

Probiotics in inflammatory bowel disease: a critical review (English)

1 reference

inflammatory bowel diseases

8 August 2017

main subject

0 references

0 references

Antoine Cortot

3

0 references

Pierre Desreumaux

object named as

Pierre Desreumaux

series ordinal

5

0 references

Jean-Frédéric Colombel

series ordinal

4

object named as

Jean-Frédéric Colombel

1 reference

8 August 2017

1

Cyrus P Tamboli

1 reference

8 August 2017

Christel Caucheteux

2

1 reference

8 August 2017

publication date

1 October 2003

1 reference

Best Practice and Research: Clinical Gastroenterology

8 August 2017

published in

1 reference

8 August 2017

volume

17

1 reference

8 August 2017

issue

5

1 reference

8 August 2017

page(s)

805-820

1 reference

Inflammatory Bowel Disease

8 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Lactobacillus species prevents colitis in interleukin 10 gene–deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

The assessment of faecal flora in patients with inflammatory bowel disease by a simplified bacteriological technique.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Ulcerative colitis and Escherichia coli with adhesive properties

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Fecal beta-D-galactosidase production and Bifidobacteria are decreased in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Development of anaerobic fecal flora in healthy newborn infants

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Users' guides to the medical literature. I. How to get started. The Evidence-Based Medicine Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Assessing the methodological quality of published papers

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Escherichia coli for ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin).

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Pouchitis: result of microbial imbalance?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Pouchitis after ileal pouch-anal anastomosis: a Pouchitis Disease Activity Index.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Probiotics in chronic pouchitis: restoring luminal microbial balance

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Irritable pouch syndrome: a new category of diagnosis for symptomatic patients with ileal pouch-anal anastomosis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

J ileal pouch-anal anastomosis for chronic ulcerative colitis: complications and long-term outcome in 1310 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Saccharomyces boulardii in maintenance treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Public health issues arising from microbiological and labelling quality of foods and supplements containing probiotic microorganisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Probiotics, prebiotics or 'conbiotics'?

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Lactobacillus casei subsp. rhamnosus sepsis in a patient with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Possible role of catheters in Saccharomyces boulardii fungemia

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Treatment of murine colitis by Lactococcus lactis secreting interleukin-10.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Prospective study of the incidence, timing and treatment of pouchitis in 104 consecutive patients after restorative proctocolectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Pouchitis following pelvic pouch operation for ulcerative colitis. Incidence, cumulative risk, and risk factors

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

Pouchitis after ileal pouch-anal anastomosis for ulcerative colitis occurs with increased frequency in patients with associated primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1016%2FS1521-6918%2803%2900076-3

7 January 2021

10.1016/S1521-6918(03)00076-3

Identifiers

DOI

1 reference

8 August 2017

1 reference